Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Nestle to cut artificial colourings from all products by end-2026
Nestle is set to eliminate all artificial food colorings globally by the end of 2026, a significant move by the major food producer. This initiative, driven by consumer demand for healthier options and scrutiny of ingredients, extends beyond their existing efforts in the United States. The company invested heavily in research and development to find natural alternatives, aiming for simpler recipes that resonate with consumers.
USFDA inspects Auroactive Pharma's manufacturing unit in Andhra Pradesh
Aurobindo Pharma announced that the United States Food and Drug Administration (US FDA) conducted an inspection at Auroactive Pharma (a wholly owned subsidiary of the Company), which manufactures Active Pharmaceutical Ingredients (API) & Pharmaceutical Formulation Intermediates, situated at Sy Nos 231, 285 to 291, Sancham Village, Ranasthalam Mandal, Srikakulam District, 523 409, Andhra Pradesh, from 22 June 2026, to 26 June 2026.
Venus Remedies gets Saudi FDA approval for speciality oncology therapy
Venus Remedies Limited has secured its first global marketing authorization for its specialty oncology therapy, Plerixafor, from the Saudi Food and Drug Authority (SFDA). This hematopoietic stem cell mobilizer is crucial for patients undergoing stem cell transplantation for multiple myeloma and non-Hodgkin lymphoma.
Venus Remedies receives Saudi FDA approval for Plerixafor
Venus Remedies has received Marketing Authorization from the Saudi Food and Drug Authority (SFDA) for Plerixafor. This is the first Marketing Authorization Venus Remedies has secured for Plerixafor anywhere in the world. It is also a deliberate step in the company's move toward complex, higher-value specialty injectables in oncology and critical care, replacing reliance on commodity injectable volumes with diifferentiated therapies in regulated markets.
Vidhi Specialty Food Ingredients consolidated net profit rises 10.50% in the March 2026 quarter
Sales rise 12.01% to Rs 122.68 crore
Biocon rolls out two biosimilars in US market
Biocon has launched two new biosimilar medicines, Bosaya and Aukelso, in the United States. These drugs treat serious bone conditions. They are now available through specialty pharmacies and healthcare providers. The US Food and Drug Administration previously approved them. This launch expands Biocon's portfolio and aims to provide affordable treatment options for patients.